Also known as: Yale
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
U.S. regulators have received more than 1,400 reports since 2021 involving AI-enabled surgical devices, including allegations of botched surgeries and misidentified body parts. The FDA has authorized over 1,300 AI-integrated medical devices.
